Summary:
In this podcast, recorded at the February 2024 IO360º summit, biopharma, finance and investment experts discuss the fundability features of IO biotechs, and the current pharma needs that will drive potential partnerships or M&A. 

Moderater:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Panelists: 
Irina Margine, PhD, Principal, Biotech Private Equity, Wellington Management
Khalil Barrage, Managing Partner, Invus Group
Jeffrey Bockman, PhD, EVP, Oncology and Virology Practices, Lumanity
Emmett Schmidt, MD, PhD, VP, Clinical Oncology, External Collaborations, Merck
Gayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZeneca

For more information, go to IO360summit.com.